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Abstract: The synthesis, radiolabeling and in vitro evaluation of new silicon-fluoride 
acceptor (SiFA) derivatized D2-receptor ligands is reported. The SiFA-technology 
simplifies the introduction of fluorine-18 into target specific biomolecules for Positron-
Emission-Tomography (PET). However, one of the remaining challenges, especially for 
small molecules such as receptor-ligands, is the bulkiness of the SiFA-moiety. We 
therefore synthesized four Fallypride SiFA-conjugates derivatized either directly at the 
benzoic acid ring system (SiFA-DMFP, SiFA-FP, SiFA-DDMFP) or at the butyl-side 
chain (SiFA-M-FP) and tested their receptor affinities. We found D2-receptor affinities for 
all compounds in the nanomolar range (Ki(SiFA-DMFP) = 13.6 nM, Ki(SiFA-FP) = 33.0 nM,  
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Ki(SiFA-DDMFP) = 62.7 nM and Ki(SiFA-M-FP) = 4.21 nM). The radiofluorination showed highest 
yields when 10 nmol of the precursors were reacted with [18F]fluoride/TBAHCO3 in 
acetonitrile. After a reversed phased cartridge purification the desired products could be 
isolated as an injectable solution after only 10 min synthesis time with radiochemical 
yields (RCY) of more than 40% in the case of SiFA-DMFP resulting in specific activities 
>41 GBq/µmol (>1,100 Ci/mmol). Furthermore, the radiolabeled products were shown to 
be stable in the injectable solutions, as well as in human plasma, for at least 90 min. 
Keywords: fluorine; isotopic labeling; positron emission tomography; radiopharmaceuticals; 
silicon 
 
1. Introduction 
Positron-Emission-Tomography (PET) is a non-invasive imaging technique using contrast-agents 
(radiotracers) labeled with radionuclides such as fluorine-18 which undergo positron emission decay. 
The resulting positron annihilates with an electron, producing two gamma photons, emitted at a 180° 
angle, which can be detected in coincidence with high sensitivity, thus yielding a spatial resolution in 
the mm-range. Although a high number of radiotracers has been developed only a limited number are 
commonly used as a result of their sometimes cumbersome and difficult synthesis. 
The short half-life of many PET-nuclides (18F t½ = 109.7 min) makes it necessary to produce the 
radiotracer on site, resulting in high investment costs. The effort for a radiotracer synthesis is nearly 
independent of the number of patient doses produced per synthesis run. Therefore, PET-centers usually 
focus on the application of well-established radiotracers such as the glucose derivative 18F[FDG] 
(18F-2-fluoro-2-desoxyglucose) and only a few large PET-centers are able to provide a large number of 
other tracers. To bridge this gap, the development of new labeling techniques for the easy introduction 
of fluorine-18 into radiotracers without costly equipment would be favorable. A promising approach to 
simplify the radionuclide introduction significantly is the exploitation of the strong silicon-fluorine  
(Si–F) bond [1,2]. The silicon fluoride acceptor (SiFA) method, based on the efficient isotopic  
non-radioactive 19F for radioactive 18F exchange at the silicon atom, was recently developed and 
applied for simple one- and two-step 18F-fluorinations of peptides [3]. The radiosynthesis of different 
SiFA-derivatized peptides (RGD-, octreotate-, as well as a bombesin-analogue) resulted in specific 
activities of up to 680 GBq/µmol (18.4 Ci/µmol) for the final radiotracers, surprisingly high for a 
carrier added radiosynthesis [4]. This finding can be explained by DFT (density functional theory) 
model calculations. The most convenient feature of this SiFA labeling technique is that a final HPLC 
purification of the radiotracer from the precursor is not necessary, since labeling precursor and labeled 
product are identical. Another approach with Si-18F bearing building blocks was used for the in vivo 
evaluation of a Si-18F-derivatized bombesin derivative in tumor-bearing rodents [5,6]. However, a 
heating—as well as an HPLC-purification step—were necessary to obtain the final 18F-labeled 
compound in high specific activities. Most recently, the implementation of new functionalized SiFAs 
for the kit-like 18F-labeling of biomolecules was reported [7-10]. In in vivo studies, the use of  
SiFA-amounts as low as a few nanomoles resulted in 18F-labeled proteins with specific activities of up 
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to 10–50 GBq/µmol (270–1,350 Ci/mmol), which would be suitable for receptor-imaging with PET. In 
this particular study, we aimed at evaluating the applicability of the SiFA technique for the 
derivatization of small molecule radiotracers, such as the D2 receptor ligands fallypride (FP, 1), 
desmethoxyfallypride (DMFP, 2) and raclopride (3). It was expected that the original SiFA building 
block, which cannot be extensively modified without losing its stability against hydrolysis, might have 
a detrimental influence on the binding affinity of the SiFA derivatized D2 receptor ligands. Several new 
Si-F bearing derivatives derived from basic model compounds were analyzed recently and evaluated as 
to their stability in aqueous solution with regard to the substitution pattern at the silicon atom [11]. The 
results are consistent with our previous findings that at least two sterically hindered substituents at the 
silicon atom are necessary to preserve the stability of the silicon-fluorine bond in vitro [3]. 
With respect to these steric requirements, SiFA derived model compounds of commonly used PET 
imaging agents were synthesized to evaluate the potential of the SiFA-concept for the syntheses  
of SiFA-type small molecule radiotracers. The benzamide derivatives [18F]fallypride (1),  
[18F]-desmethoxyfallypride (2) and [11C]raclopride (3) radiotracers used for the PET-imaging of the 
dopaminergic system, were chosen as model compounds for this study [12,13] (Figure 1). All 
compounds are D2-receptor antagonists, which differ mainly in the receptor affinity, in the nanomolar 
(desmethoxyfallypride, raclopride) and picomolar range (fallypride), respectively [14]. These imaging 
agents are used for the diagnosis of different neurological disorders related to the dopaminergic system 
such as parkinsonism and craving [15,16]. 
Figure 1. D2-receptor affine benzamide-derivatives used for PET-neuroimaging:  
[18F]-Fallypride (FP, 1); [18F]-Desmethoxyfallypride (DMFP, 2); [11C]-Raclopride (3). 
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Due to the bulkiness of the SiFA-moiety that has to be introduced into the potential radiotracer, the 
ligand fallypride, having one of the highest affinities to the D2 receptor, was tested first as a scaffold 
for SiFA derivatization since even a certain loss of target affinity would not necessarily result in an 
unusable PET radiotracer. The two different strategies applied were: (i) the integration of the SiFA 
building block into the fallypride/desmethoxyfallypride general structure and (ii) the coupling of an 
already existing SiFA compound, namely SiFA-maleimide (SiFA-M, [17]), to a fallypride derivatized 
with an SH moiety at the butyl side chain (Figure 2). Besides the prerequisite of a good binding 
affinity to the targeted D2-receptor, the radiolabeling has to yield a radiotracer with a sufficiently high 
specific activity for D2 receptor imaging with PET. In order to simplify the radiosynthesis of the 
desired 18F fluorinated radiotracer, we only studied one-step radiosyntheses using the non-radioactive 
standards directly as the labeling precursors (isotopic exchange reaction). Hence, the amount of the 
precursor used determines the specific activity (in relation to the amount of radioactivity used  
for labeling). 
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Figure 2. Synthesized SiFA-conjugated Fallypride-derivatives 4a–c, 5. 
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The use of 10 nanomoles precursor would result in specific activities comparable to those of 
conventionally synthesized 18F radiotracers. If, e.g., 500 MBq (13.5 mCi) 18F are incorporated into  
10 nmol of the labeling precursor the resulting specific activity would be as high as 50 GBq/µmol 
(1,350 Ci/mmol). Consequently, the identification of the lowest limit of the ratio precursor 
amount/concentration necessary for a sufficient radiochemical yield (introduction of fluorine-18) was 
the second important focus of this work. 
2. Results and Discussion 
2.1. Precursor Syntheses 
The preparation of the SiFA-modified carboxylic acids 12a and 12b (Scheme 1) followed a general 
method described in our previous work [17]. Single crystals of compounds 10b, 12a and 12b suitable 
for X-ray diffraction analysis were obtained as colorless needles by re-crystallization from diethyl 
ether/hexane. The molecular structures of these compounds are presented in Figures 3–5, and selected 
bond distances and bond angles are collected in Table 1. 
All compounds crystallized monoclinically with eight (10b) or four (12a, 12b) molecules in the unit 
cell. There are two crystallographically independent molecules in the unit cell of compound 10b 
(Figure 3) with one of them being disordered. In Table 1, only the data for the non-disordered 
molecule are given. The silicon atoms in these compounds are four-coordinate and show each a 
distorted tetrahedral configuration with average angles of 109.59 (10b), 109.70 (12a) and 109.04 
(12b). The largest deviations from the tetrahedral angle are found for C(11)–Si–C(15) (119.40°, 12b) 
and F–Si–C(11) (104.15°, 12a). 
The Si-F distances are similar and fall in the range between 1.6033(11) (12b) and 1.6133(14) (10b) 
Å. They are slightly longer as compared to t-BuPh2SiF (1.6004(10) Å) but close to the Si–F distances 
in other SiFA-compounds [17]. Interestingly, intramolecular O(1)–HLO(11A) and O(11)–HLO(1) 
hydrogen bridges (Table 1) link the molecules of compound 10b to form a one-dimensional polymer 
chain as presented in Figure 3. A noteworthy feature is the asymmetric intramolecular O(1)–HLO 
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(2A) hydrogen bridge that links two molecules of 12a and 12b, respectively, to give a dimer (Table 2). 
Such hydrogen bridges are common for solid state structures of p-silylarylcarbonic acids [17]. 
Scheme 1. Synthesis of the silicon-modified carboxylic acids 12a and 12b. 
t-Bu2FSi
t-BuLi, t-Bu2SiF2,
Et2O,
MeOH,
HCl (cat.)PCC, CH2Cl2
O
OMe
Br R
OH
OMe
Br R
OTBDMS
OMe
Br R
OMe
R
OTBDMS
t-Bu2FSi
OMe
R
OH
t -Bu2FSi
OMe
R
O
t -Bu2FSi
OMe
R
OHO
a: R = H
b: R = OMe
6a, b 7a, b 8a, b
9a, b10a, b11a, b
12a, b
NaBH4,
MeOH, H2O
imidazole,
t -BuMe2SiCl,
CH2Cl2
KMnO4, CH2Cl2,
t-BuOH,
NaH2PO4/H3PO4,
TBDMS = t -BuMe2Si
PCC = (C5H6N)+(CrClO3)-
 
Figure 3. Molecular structure of 10b (left) and simplified representation of the 
intermolecular hydrogen bridges (right). Atomic displacement parameters are drawn at 
30% probability level. 
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Figure 4. Molecular structure of 12a. Atomic displacement parameters are drawn at 30% 
probability level. 
 
Figure 5. Molecular structure of 12b. Atomic displacement parameters are drawn at 30% 
probability level. 
 
Table 1. Selected bond lengths [Å] and angles [°] for 10b, 12a, 12b. 
Bond lengths [Å] 10b 12a 12b 
Si(1)-F(1) 1.6133(13) 1.6125 (10) 1.6033 (11) 
Si(1)-C(1) 1.8712(19) 1.8696 (15) 1.8695 (17) 
Si(1)-C(11) 1.893(2) 1.8846 (16) 1.872 (2) 
Si(1)-C(15) 1.888(2) 1.8911 (17) 1.875 (2) 
Bond angles [°]    
F(1)-Si(1)-C(1) 104.78(8) 105.12 (6) 104.67 (8) 
F(1)-Si(1)-C(11) 104.97(9) 104.15 (7) 105.61 (8) 
F(1)-Si(1)-C(15) 105.23(9) 105.20 (6) 104.81 (8) 
C(1)-Si(1)-C(11) 112.55(9) 112.36 (7) 109.04 (9) 
C(1)-Si(1)-C(15) 109.59(9) 109.70 (7) 111.99 (9) 
C(11)-Si(1)-C(15) 118.44(10) 118.96 (7) 119.40 (10) 
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Table 2. Hydrogen-bonding geometry [Å, °]. 
Compoun
d 
D-H...A  d(D-H) d(H...A
) 
d(D...A) <(DHA
) 
10b O(1)-H(1)...O(11A)  0.82(3) 1.87(3) 2.682(2) 168(2) 
10b O(11)-H(11)...O(1) 0.83(3) 1.86(3) 2.695(2) 178(3) 
12a O(1)-H(1)...O(2A)  0.80(2) 1.84(2) 2.641(2) 173(2) 
12b O(1)-H(1)...O(2A)  1.22(4) 1.42(4) 2.640(2) 177(3) 
The test reaction for the coupling of carboxylic acids to (S)-(1-allylpyrrolidin-2-yl)methanamine 
was performed according to a literature procedure [12], using the carboxylic acid 12c [17] (Scheme 2). 
Dicyclohexylcarbodimide (DCC) was used for the activation of the carboxylic acid and the fallypride-
derivative was obtained in poor yield of 11%. In order to achieve a higher yield, the more powerful 
activating agent N-hydroxysuccinimide (HO-Su) was added to the reaction mixture (Scheme 3).  
SiFA-DMFP 4a and SiFA-FP 4b were obtained in yields of up to 41% after purification via column 
chromatography. Both compounds were characterized via two-dimensional NMR spectroscopy and 
high resolution mass spectrometry. In the latter, the molecular peak was found with high precision. 
Scheme 2. Coupling reaction of the SiFA-carboxylic acid 12c to the (S)-(1-allyl-pyrrolidin-
2-yl)methyl-amine. 
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Scheme 3. Coupling reaction of the SiFA-carboxylic acids to the (S)-(1-allyl-pyrrolidin-2-
yl)methyl-amine in the presence of N-hydoxy-succinimide. 
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SiFA-M (1-(4-(di-tert-butylfluorosilyl)phenyl)-1H-pyrrole-2,5-dione) was synthesized according to 
a recently described procedure [17] and reacted with FP-Thiol [(S)-N-((1-allylpyrrolidin-2-yl)methyl)-
5-(3-mercaptopropyl)-2,3-dimethoxybenzamide] in a water/acetonitrile mixture at pH 7.2. This 
Michael-addition was monitored via analytical HPLC and was completed within 10 min at ambient 
temperature. After semipreparative HPLC purification and lyophilization, the product SiFA-M-FP, 5, 
was isolated in 49% yield and identified via ESI-MS and NMR spectroscopy. 
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2.2. In Vitro Evaluation 
Compounds 4a–c and 5 (SiFA-DMFP 4a, SiFA-FP 4b, SiFA-DDMFP 4c and SiFA-M-FP 5) were 
tested for their affinity towards the human D2 receptor (Table 3). All tested compounds showed  
Ki-values in the nanomolar range. As expected for the derivatization of a small molecule with the 
bulky SiFA-moiety, the affinities are reduced by factors ranging between 22 [SiFA-DMFP 4a 
compared to desmethoxyfallypride (2)], 44 [SiFA-M-FP 5 compared to fallypride (1)] and 342 [SiFA-FP 
4b compared to fallypride (1)]. Interestingly, SiFA-DMFP (4a) displays a higher affinity to the 
receptor compared to SiFA-FP (4b) and SiFA-DDMFP (4c). Among the newly developed substances 
4a–c and 5, SiFA-M-FP (5) displays the highest binding affinity which might be explained with the 
higher distance of the derivatization site (SiFA is bound to the butyl side chain) to the receptor binding 
parts of the molecule. The methoxy moiety, which distinguishes the high affinity tracer fallypride (1) 
from the medium-affinity tracer desmethoxyfallypride (2) leads to a loss of binding affinity in the pair 
SiFA-DMFP 4a/SiFA-FP 4b inversely to the situation with fallypride (1)/desmethoxyfallypride (2). 
We can therefore assume that the benzoic acid ring system still influences the binding affinity but 
binds most probably in a different conformation to the binding site at the D2-receptor. However, we 
chose fallypride (1) as a scaffold for this study, because even an unavoidable decrease in binding-
affinity towards the D2-receptor might still lead to a medium affinity ligand comparable to raclopride 
(3—the gold standard for D2-receptor imaging with PET). Therefore, the direct comparison of  
SiFA-M-FP (5) to [11C]raclopride [11C]-3, which is most frequently used in clinical studies of the 
dopaminergic system, looked more encouraging: When comparing the medium-affinity D2-receptor 
radiotracer raclopride (Ki = 1.21 nM) to SiFA-M-FP (5; Ki = 4.21) and SiFA-DMFP (4a; Ki = 13.6 nM) 
the affinity is only reduced by the factor 3.5 and 11, respectively. Thus, a successful in vivo D2 
receptor imaging using radiolabeled SiFA-M-FP (5) or SiFA-DMFP (4a) might be possible. 
Table 3. D2-receptor affinities of the developed substances 4a–c, 5. 
Compound Ki (nM ± SEM *) 
Fallypride 0.0965 ± 0.0153 
Desmethoxyfallypride 0.630 ± 0.089 
Raclopride 1.21 ± 0.43 
SiFA-DMFP, 4a 13.6 ± 4.3 
SiFA-FP, 4b 33.0 ± 7.6 
SiFA-DDMFP, 4c 62.7 ± 16.9 
SiFA-M-FP, 5 4.21 ± 0.41 
* SEM: standard error of the mean. 
2.3. Radiolabeling 
Radiolabeling reactions based on isotopic exchange usually have the drawback of a limited specific 
activity (SA), as the precursor cannot be separated from the final product. It is therefore crucial for  
in vivo applications of the synthesized radiotracer to reduce the precursor amount to the absolute 
minimum. Our previous studies showed that for radiofluorinations of small molecules such as a  
SiFA-aldehyde, amounts of 1–5 nmol were sufficient to achieve high radiolabeling yields [4]. For the 
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direct labeling of SiFA-derivatized peptides, precursor amounts of 10–25 nmol were necessary [18]. 
The highest radioactivity incorporation rates were observed when the SiFA radiolabeling was carried 
out in polar aprotic solvents such as acetonitrile or DMSO. As the SiFA-moiety gets hydrolyzed very 
quickly under basic conditions, we tested the following two mild labeling procedures in acetonitrile, 
DMF or DMSO: (a) Kryptofix2.2.2/potassium oxalate/18F− and (b) tetrabutylammonium bicarbonate/18F−. 
Table 4 summarizes the labeling of SiFA-DMFP (4a) under different labeling conditions. 
To keep the labeling procedure as simple and convenient as possible, we performed the purification 
step by using a reversed phase cartridge (SepPak C-18 light) for all tested combinations. We 
determined the 18F-incroporation of 18F− into SiFA-DMFP (4a) after a 5 min reaction time at room 
temperature with analytical radio-HPLC using samples of the crude reaction mixture. After dilution 
with 10 mL 1M HEPES buffer at pH = 4.0 (used to prevent hydrolysis) the desired radiotracer was 
purified using a reversed-phased SepPak-cartridge. The SepPak purification was necessary to remove 
unreacted 18F−, solvent and K2.2.2/potassium oxalate or TBAHCO3 from the product. After washing 
the cartridge with water, the products could be eluted very efficiently with 1 mL ethanol and were 
subsequently diluted with isotonic saline. The radiochemical yields (RCY) were calculated to the start 
of the synthesis and the radiochemical purity (RCP) analyzed by analytical radio-HPLC. Using  
SiFA-DMFP (4a) as the precursor, we found radioactivity incorporations in acetonitrile using 
TBAHCO3 of up to 61% in the crude reaction mixture (Table 4) and an overall RCY after purification 
of up to 42%. Under these conditions, the specific activity was calculated to be in the range of  
88 GBq/µmol (2.4 Ci/µmol) using a precursor amount of 5 nmol and at least 41 GBq/µmol (1.1 Ci/µmol) 
using 10 nmol precursor when starting from ~1GBq (27 mCi) 18F-fluoride. This is in the suitable range 
for D2-neuroreceptor imaging with PET. The radiochemical purity of all products was >96% after 
purification. Using DMF or DMSO, the 18F-radioactivity incorporation was drastically reduced to less 
than 25%. More importantly, the desired product could not be purified via cartridge separation. 
Likewise, the labeling procedure using K2.2.2 resulted in a lower relative 18F-incorporation as well as 
a lower RCY compared to the procedure using TBAHCO3. 
Table 4. Radiolabeling of 5–10 nmol SiFA-DMFP (4a), 5 min at ambient temperature. 
Labeling method 
(solvent) 
Amount of 
precursor 
18F-incorporation ± SD * RCY ± SD * RCP ** 
(a) K2.2.2 *** 
(acetonitrile) 
10 nmol 25.3 ± 2.5% 16.7 ± 1.4% >96% 
(b) TBAHCO3 
(acetonitrile) 
10 nmol 60.7 ± 3.1% 41.8 ± 5.7% >96% 
(b) TBAHCO3 
(acetonitrile) 
5 nmol 57.2 ± 6.2% 34.6 ± 5.6% >96% 
(b) TBAHCO3 
(DMSO) 
10 nmol 10.2 ± 0.3% n.d. <60% 
(b) TBAHCO3 
(DMF) 
10 nmol 21.4 ± 4.5% n.d. <75% 
* SD: standard deviation, all experiments were independently performed at least three times;  
** after cartridge purification. *** K2.2.2 = Kryptofix2.2.2. 
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Using these labeling conditions optimized for [18F]-SiFA-DMFP [18F]-4a, we found comparable 
radiolabeling yields and purities for [18F]-SiFA-FP ([18F]-4b) and [18F]-SiFA-DDMFP ([18F]-4c), 
whereas the radiolabeling yields for SiFA-M-FP ([18F]-5) were significantly lower (Table 5). 
Table 5. Radiolabeling of 4a–c and 5, 10 nmol, labeling method (b) in acetonitrile. 
Compound 18F-incorporation ± SD * RCY ± SD * RCP 
SiFA-DMFP, 4a 60.7 ± 3.1% 41.8 ± 5.7% >96% 
SiFA-FP, 4b 60.8 ± 2.5 % 47.3 ± 5.9% >94% 
SiFA-DDMFP, 4c 54.2 ± 6.0% 48.4 ± 0.7% >97% 
SiFA-M-FP, 5 16.6 ± 10.2% n.d. <50% 
* SD: standard deviation, all experiments were independently performed at least three times. 
Moreover, radiolabeled [18F]-SiFA-M-FP [18F]-5 could not be purified via the SepPak separation 
method described above. We can only speculate that the chemical design of the phenolic ring system 
of SiFA-maleimide leads to a significantly different stability of the SiFA-moiety compared to the 
benzamides 4a–c. This finding is in line with our previous observation that protein labeling using 
[18F]-SiFA-thiol bound to a maleimide-derivatized protein resulted in higher radiolabeling yields than 
a vice versa labeling of a thiol-derivatized protein with [18F]-SiFA-maleimide. 
The chemical purity was determined for all products by analytical HPLC at 214 nm and showed no 
side products for all radiolabeled derivatives with a RCP > 94%. The chemical stability of [18F]-SiFA-
DMFP ([18F]-4a), SiFA-FP ([18F]-4b) and SiFA-DDMFP ([18F]-4c) was determined over 4 h at room 
temperature by analytical radio-HPLC. Within this time span, no decomposition was detected. The 
plasma stability was determined for SiFA-DMFP ([18F]4a) over 90min displaying no degradation of 
the product. 
3. Experimental 
3.1. General 
All solvents used for the syntheses of 4a–c (SiFA-DMFP, SiFA-FP, SIFA-DDMFP) were purified 
by distillation from appropriate drying agents under argon atmosphere. Solvents and chemicals used in 
the synthesis of 5, SiFA-M-FP, were of analytical grade and used without further purification. 
Chemicals and solvents used for the labeling experiments were purchased in the highest available 
grade and were used without further purification. The NMR experiments were carried out with Jeol 
AS500, Bruker DRX 400, Bruker DRX 300, and Varian Mercury 200 spectrometers. Chemical shifts 
(δ) are given in ppm and are referenced to the solvent peaks, with the usual values calibrated against 
tetramethylsilane (1H, 13C, 29Si) and CFCl3 (19F). High-resolution mass spectra were obtained by using 
a Finnigan MAT95Q mass spectrometer and a LTQ Orbitrap mass spectrometer (Thermo Electron) 
using acetonitrile as the mobile phase. FT infrared spectra were recorded using a Bruker IFS 28 
spectrometer. Elemental analyses were performed on a LECO CHNS-932 analyzer. The analytical and 
semi-preparative HPLC system used was an Agilent 1200 system equipped with a raytest Gabi Star 
radioactivity detector together with a Chromolith Performance (RP-18e, 100–4.6 mm, Merck, Germany) 
and a Chromolith (RP-18e, 100–10 mm, Merck, Germany) column, respectively. SiFA-M was 
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synthesized according to a published procedure [17]. The synthesis of the thiol-substituted fallypride 
will be described elsewhere. 
3.2. Crystallography 
Crystals of compounds 10b, 12a and 12b suitable for single-crystal X-ray diffraction analyses were 
grown by re-crystallization from diethyl ether/n-hexane. Crystallographic data are summarized in 
Table 1. Intensity data were collected with a Nonius KappaCCD diffractometer with graphite-
monochromated Mo-Kα radiation. The data collections covered almost the whole sphere of the 
reciprocal space with 3 (5), 4 (7 and 8b) sets at different κ angles and 227 (5), 339 (7), 494 (8b) frames 
by ω-rotation (Δ/ω = 1°) at 2 × 160 s (5), 80 s (7), 60 s (8b) per frame. Crystal decay was monitored by 
repeating the initial frames at the end of the data collection. After analysis of the duplicate reflections, 
there was no indication of any decay. The structures were solved by direct methods (SHELXS97 [19]). 
Refinement applied full-matrix least-squares methods (SHELXL97). All H atoms were located in the 
difference Fourier map and their positions were isotropically refined with Uiso constrained at 1.2 times 
Ueq of the carrier C atom for non-methyl and 1.5 times Ueq of the carrier C atom for methyl groups. 
Atomic scattering factors for neutral atoms and real and imaginary dispersion terms were taken from 
International Tables for X-ray Crystallography [20]. The figures were created by SHELXTL. 
Crystallographic data are given in Table 6. Crystallographic data for the structures reported in this 
paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary 
material publication No. CCDC-704771, CCDC-704583 and CCDC-704772. Copies of the data can  
be obtained free of charge on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK  
(Fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk). 
Table 6. Crystallographic data for 10a, 12a and 12b. 
 10b 12a 12b 
Empirical formula C17H29FO3Si C16H25FO3Si C17H27FO4Si 
Formula mass [g/mol] 328.49 312.45 342.48 
Crystal system monoclinic monoclinic monoclinic 
Crystal size 0.44 × 0.28 × 0.10 0.40 × 0.28 × 0.20 0.28 × 0.24 × 0.20 
Space group P21/c P21/n P21/c 
a [Å] 8.0498(3) 6.91101(14) 12.866(3) 
b [Å] 35.1976(15) 16.975(3) 8.1150(16) 
c [Å] 13.5997(7) 14.529(3) 19.412(4) 
β [°] 102.644(2) 94.46(3) 108.51(3) 
V [Å3] 3759.8(3) 1699.3(6) 1921.9(7) 
Z 8 4 4 
ρcalcd.[mg/m3] 1.161 1.221 1.184 
μ [mm−1] 0.143 0.155 0.146 
F(000) 1424 672 736 
θ range [°] 1.64–27.79 2.78–27.48 2.74–27.48 
Index ranges −16 ≤ h ≤ 17 −8 ≤ h ≤ 8 −15 ≤ h ≤ 15 
 −44 ≤ k ≤ 46 −22 ≤ k ≤ 22 −10 ≤ k ≤ 10 
 −8 ≤ l ≤ 10 −18 ≤ l ≤ 18 −25 ≤ l ≤ 25 
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Table 1. Cont. 
 10b 12a 12b 
No. of reflections 
collected 
26113 17951 17285 
Completeness of θmax 
[%] 
97.3 99.8 99.8 
No. of independent 
reflections / Rint. 
8677/0.037 3872/0.022 4401/0.022 
No. of reflections 
observed with  
[I > 2σ(I)] 
6140 2389 1602 
No. of refined 
parameters 
443 200 211 
GoF(F2) 1.031 0.900 0.729 
R1(F) [I > 2σ(I)] 0.0517 0.0362 0.0364 
wR2(F2) (all data) 0.1409 0.0924 0.0905 
(Δ/σ)max 0.001 0.000 0.000 
Largest differnce 
peak/hole [e / Å3] 
0.448/−0.251 0.199/−0.237 0.106/−0.171 
3.3. Chemistry 
(5-Bromo-2-methoxyphenyl)methanol (7a). A solution of sodium borohydride (0.94 g, 24.8 mmol,  
1.0 equiv.) in H2O (30 mL) was added to a solution of the benzaldehyde derivative 6a (5.33 g, 24.8 mmol) 
in methanol (200 mL). After stirring at room temperature for 24 h, methanol was evaporated and the 
aqueous residue was diluted with diethyl ether (200 mL). The aqueous phase was extracted with 
diethyl ether (3 × 100 mL), the combined organic layers were dried with MgSO4, filtered and the 
filtrate was evaporated to afford 7a (5.06 g, 23.31 mmol, 94%) as colourless oil. 1H-NMR (400.13 MHz, 
CDCl3): δ (ppm) = 7.39 (d, 4J(1H-1H) = 2.4 Hz, 1H, C(6)H), 7.33 (dd, 3J(1H-1H) = 8.8 Hz,  
4J(1H-1H) = 2.4 Hz, 1H, C(4)H), 6.72 (d, 3J(1H-1H) = 8.8 Hz, 1H, C(3)H), 4.61 (s, 2H, CH2),  
3.81 (s, 3H, OCH3), 2.35 (s, 1H, OH). 
(5-Bromo-2,3-dimethoxyphenyl)methanol (7b). The procedure was analogous to the synthesis of 7a. 
The benzaldehyde derivative 6b (5.35 g, 21.83 mmol) gave alcohol 7b (5.04 g, 20.40 mmol, 93%) as a 
colourless oil. 1H-NMR (200.13 MHz, CDCl3): δ (ppm) = 7.05 (d, 4J(1H-1H) = 2.3 Hz, 1H, C(4)H), 
6.93 (d, 4J(1H-1H) = 2.3 Hz, 1H, C(6)H), 4.59 (d, 3J(1H-1H) = 5.6 Hz, 2H, CH2), 3.80 (s, 3H, OCH3), 
3.78 (s, 3H, OCH3), 2.93 (t, 3J(1H-1H) = 5.6 Hz, 1H, OH). 
(5-Bromo-2-methoxybenzyloxy)(tert-butyl)dimethylsilane (8a). To a solution of 7a (5.00 g, 23.00 mmol) 
in dichloromethane (150 mL) imidazole (2.03 g, 29.89 mmol, 1.3 equiv.) was added and the suspension 
was stirred at ambient temperature for 10 min. t-Butyldimethylchlorosilane (t-BuMe2SiCl, 4.16 g, 
27.59 mmol, 1.2 equiv.) was added and stirring was continued for 20 h. For work-up the mixture was 
diluted with H2O (40 mL) and the aqueous phase was extracted with dichloromethane (3 × 50 mL). 
The combined organic layers were dried with MgSO4, filtered and the solvent was evaporated to afford 
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8a (7.10 g, 21.43 mmol, 93%) as a red oil. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 7.57 (d,  
4J(1H-1H) = 2.5 Hz, 1H, C(6)H), 7.29 (dd, 4J(1H-1H) = 2.5 Hz, 3J(1H-1H) = 8.6 Hz, 1H, C(4)H), 6.66 (d, 
3J(1H-1H) = 8.6 Hz, 1H, C(3)H), 4.71 (s, 2H, CH2), 3.77 (s, 3H, OCH3), 0.97 (s, 9H, CCH3),  
0.13 (s, 6H, SiCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 154.9 (s, C(2)), 132.2 (s, C(6)), 
130.0 (s, C(4)), 129.5 (s, C(1)), 113.0 (s, C(3)), 111.1 (s, C(5)), 59.7 (s, CH2), 55.3 (s, OCH3),  
26.0 (s, CCH3), 18.5 (s, C(CH3)3, −5.3 (s, SiCH3). 
(5-Bromo-2,3-dimethoxybenzyloxy)(tert-butyl)dimethylsilane (8b). The procedure was analogous to the 
synthesis of 8a. The benzyl alcohol derivative 7b (4.93, 19.95 mmol) gave the silylated alcohol 8b 
(5.88g, 16.27 mmol, 82%) as a slightly yellowish oil. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 7.08 
(d, 4J(1H-1H) = 2.3 Hz, 1H, C(4)H), 6.82 (d, 4J(1H-1H) = 2.2 Hz, 1H, C(6)H), 4.62 (s, 2 H, CH2), 3.72 
(s, 3H, OCH3), 3.67 (s, 3H, OCH3), 0.83 (s, 9H, CCH3), 0.00 (s, 6H, SiCH3). 
Di-tert-Butyl(3-((tert-butyldimethylsilyloxy)methyl)-4-methoxyphenyl)fluorosilane (9a). To a stirred 
solution of 8a (5.00 g, 15.09 mmol) in dry diethyl ether (150 mL), t-BuLi (17.8 mL, 1.7 mol/L,  
30.18 mmol, 2.0 equiv.) was added dropwise at −78 °C. After stirring for 10 min t-Bu2SiF2 (3.00 g, 
16.60 mmol, 1.1 equiv.) was added and stirring was continued for 19 h while the reaction mixture was 
allowed to warm to ambient temperature. The mixture was washed with H2O (50 mL) and the aqueous 
phase was extracted with diethylether (3 × 50 mL). The combined organic layers were dried with 
MgSO4, filtered and the solvent was evaporated to afford 9a (5.77 g, 13.98 mmol, 93%) as a colourless 
oil. 1H-NMR (300.13 MHz, CDCl3): δ (ppm) = 7.64 (s, 1H, C(6)H), 7.38 (d, 3J(1H-1H) = 8.1 Hz, 1H, 
C(4)H), 6.73 (d, 3J(1H-1H) = 8.6 Hz, 1H, C(3)H), 4.69 (s, 2H, CH2), 3.70 (s, 3H, OCH3), 0.96 (s, 18H, 
CCH3), 0.85 (s, 9H, CCH3), 0.00 (s, 6H, SiCH3). 13C[1H]-NMR (75.48 MHz, CDCl3): δ (ppm) = 157.7 
(s, C(2)), 134.4 (d, 3J(13C-19F) = 3.9 Hz, C(6)), 132.4 (d, 3J(13C-19F) = 4.5 Hz, C(4)), 129.3 (s, C(1)), 
124.3 (d, 2J(13C-19F) = 13.9 Hz, C(5)), 109.2 (s, C(3)), 60.5 (s, CH2), 55.3 (s, OCH3), 27.8 (s, CCH3), 
26.4 (s, CCH3), 20.8 (d, 2J(13C-19F) = 12.5 Hz, C(CH3)3), 18.8 (s, C(CH3)3, −4.9 (s, SiCH3). 19F-NMR 
(282.38 MHz, CDCl3): δ (ppm) = −189.1 (s, 1J(19F-29Si) = 297 Hz). 29Si-NMR (59.63 MHz, CDCl3):  
δ (ppm) = 20.6 (s, Si(CH3)2tBu), 14.7 (d, 1J(29Si-19F) = 297 Hz, SiFtBu2). Elemental analysis 
calculated (%) for C22H41FO2Si2 (412.73 g/mol): C 64.0, H 10.0; found (%): C 63.8, H 9.6. HR-MS 
(GC-EI): calculated for C22H41O2F28SNa+ 435.2521, found 435.2530 [M+Na+]. 
Di-tert-Butyl(3-((tert-butyldimethylsilyloxy)methyl)-4,5-dimethoxyphenyl)-fluorosilane (9b). To a 
stirred solution of 8b (5.70 g, 15.77 mmol) in dry diethylether (150 mL) and dry THF (50 mL) t-BuLi 
(18.6 mL, 1.7 mol/L, 31.55 mmol, 2.0 equiv.) was added dropwise at −78 °C. After stirring for 5 min  
t-Bu2SiF2 (3.13 g, 17.35 mmol, 1.1 equiv.) was added and stirring was continued for 19 h while the 
reaction mixture was allowed to warm to ambient temperature. The mixture was concentrated in vacuo 
and the aqueous residue dissolved in chloroform. The aqueous phase was extracted with chloroform  
(4 × 100 mL) and the combined organic layers were concentrated in vacuo, dried with MgSO4 and 
filtered. The solvent was evaporated and the crude product was purified by column chromatography 
(hexane/diethylether = 20/1) to afford 9b (4.74 g, 10.71 mmol, 68%) as a colorless oil. 1H-NMR 
(200.13 MHz, CDCl3): δ (ppm) = 7.33 (s, 1H, C(6)H), 7.07 (s, 1H, C(4)H), 4.82 (s, 2H, CH2),  
3.89 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 1.08 (s, 18H, CCH3), 0.95 (s, 9H, CCH3), 0.11 (s, 6H, SiCH3). 
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13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 151.5 (s, C(2)), 147.0 (s, C(3)), 134.4 (s, C(1)), 128.4 
(d, 2J(13C-19F) = 13.7 Hz, C(5)), 125.1 (d, 3J(13C-19F) = 4.5 Hz, C(6)), 116.5 (d, 3J(13C-19F) = 3.9 Hz, 
C(4)), 60.5 (s, CH2 or OCH3), 60.1 (s, CH2 or OCH3), 55.8 (s, OCH3), 27.4 (s, CCH3), 25.9 (s, CCH3), 
20.3 (d, 2J(13C-19F) = 12.4 Hz, C(CH3)3), 18.3 (s, C(CH3)3, −5.3 (s, SiCH3). 19F-NMR (282.38 MHz, 
CDCl3): δ (ppm) = −189.1 (s, 1J(19F-29Si) = 298 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 20.7 
(s, Si(CH3)2tBu), 14.3 (d, 1J(29Si-19F) = 298 Hz, SiFtBu2). Elemental analysis calculated (%) for 
C23H43FO3Si2 (412.73 g/mol): C 62.4, H 9.8; found (%): C 62.2, H 9.6. HR-MS (GC-EI): calculated 
for C23H43O3F28SiNa+ 465.2627, found 465.2638 [M+Na+]. 
(5-(di-tert-Butylfluorosilyl)-2-methoxyphenyl)methanol (10a). To a stirred solution of 9a (4.90 g,  
11.88 mmol) in methanol (250 mL) catalytic amounts of concentrated HCl was added. After stirring at 
room temperature for 19 h, methanol was evaporated and the residue dissolved in H2O and diethyl 
ether. The aqueous phase was extracted with diethyl ether (3 × 50 mL) and the combined organic 
layers were washed with saturated NaHCO3-solution (50 mL), dried with MgSO4, and filtrated. The 
solvent was evaporated to afford 10a (3.05 g, 10.22 mmol, 86%) as a colorless oil. 1H-NMR (400.13 MHz, 
CDCl3): δ (ppm) = 7.50 (d, 3J(1H-1H) = 8.1 Hz, 1H, C(4)H), 7.47 (s, 1H, C(6)H), 6.89 (d,  
3J(1H-1H) = 8.1 Hz, 1H, C(3)H), 4.67 (d, 3J(1H-1H) = 6.2 Hz, 2H, CH2), 3.85 (s, 3H, OCH3),  
2.51 (t, 3J(1H-1H) = 6.2 Hz, 1H, OH), 1.03 (s, 18H, CCH3). 13C[1H]-NMR (400.13 MHz, CDCl3):  
δ (ppm) = 158.7 (s, C(2)), 135.2 (d, 3J(13C-19F) = 4.3 Hz, C(6)), 134.3 (d, 3J(13C-19F) = 4.1 Hz, C(4)), 
128.3 (s, C(1)), 124.5 (d, 2J(13C-19F) = 13.9 Hz, C(5)), 109.6 (s, C(3)), 62.2 (s, CH2), 55.0 (s, OCH3), 
27.3 (s, CCH3), 20.2 (d, 2J(13C-19F) = 12.4 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3):  
δ (ppm) = −189.0 (s, 1J(19F-29Si) = 297 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.6 (d, 
1J(29Si-19F) = 297 Hz). Elemental analysis calculated (%) for C16H27FO2Si (298.47 g/mol): C 64.4, H 
9.1; found (%): C 64.1, H 9.2. IR (KBr): ν (cm−1) = 3326 (ν(OH)). HR-MS (GC-EI): calculated for 
C16H27O2F28Si+ 298.1759, found 298.1761 [M+]. 
(5-(di-tert-Butylfluorosilyl)-2,3-dimethoxyphenyl)methanol (10b). The procedure was analogous to the 
synthesis of 10a starting from the protected alcohol 9b (4.69, 10.59 mmol). The crude product was 
purified by column chromatography (hexane/diethylether = 3/1 → hexane/diethylether = 2/1 → 
hexane/diethylether = 1/1 → hexane/diethylether) to afford 10b (3.13, 9.53 mmol, 90%) as a white 
crystalline solid of m.p. 80 °C. 1H-NMR (200.13 MHz, CDCl3): δ (ppm) = 7.14 (d, 4J(1H-1H) = 0.9 Hz, 
1H, (C4)H), 7.03 (d, 4J(1H-1H) = 0.9 Hz, 1H, (C6)H), 4.61 (s, 2H, CH2), 3.81 (s, 3H, OCH3),  
3.80 (s, 3H, OCH3), 3.17 (s, 1H, OH), 1.00 (s, 18H, CCH3). 13C[1H]-NMR (75.48 MHz, CDCl3):  
δ (ppm) = 152.1 (s, (C2)), 148.6 (s, (C3)), 134.5 (s, (C1)), 129.3 (d, 2J(13C-19F) = 13.6 Hz, (C5)), 126.9 
(d, 3J(13C-19F) = 4.1 Hz, (C4)), 117.7 (d, 3J(13C-19F) = 3.9 Hz, (C6)), 61.3 (s, CH2), 61.1 (s, OCH3), 
56.1 (s, OCH3), 27.8 (s, CCH3), 20.6 (d, 2J(13C-19F) = 12.4 Hz, C(CH3)3). 19F-NMR (282.38 MHz, 
CDCl3): δ (ppm) = −188.5 (s, 1J(19F-29Si) = 298 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.1 
(d, 1J(29Si-19F) = 298 Hz). Elemental analysis calculated (%) for C17H29FO3Si (328.19 g/mol): C 62.2, 
H 8.9; found (%): C 62.0, H 8.9. IR (KBr): ν (cm−1) = 3294 (ν(OH)). HR-MS (GC-EI): calculated for 
C17H29O3F28Si+ 328.1865, found 328.1869 [M+]. 
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(3-(Bromomethyl)-4-methoxyphenyl)di-tert-butylfluorosilane (10c). The procedure was analogous to 
the synthesis of 10a starting from 9a (2.80 g, 6.78 mmol) and concentrated HBr (50 mL). After 
crystallisation from diethyl ether/hexane, 10c (1.80 g, 4.98 mmol, 73%) was obtained as white 
crystalline solid of m.p. 61 °C. 1H-NMR (300.13 MHz, CDCl3): δ (ppm) = 7.54–7.57 (m, 2 H, C(4)H 
und C(6)H), 6.93 (d, 3J(1H-1H) = 8.7 Hz, 1H, C(3)H), 4.61 (s, 2H, CH2), 3.94 (s, 3H, OCH3), 1.08 (s, 
18H, CCH3). 13C[1H]-NMR (75.48 MHz, CDCl3): δ (ppm) = 159.1 (s, C(2)), 137.1 (d,  
3J(13C-19F) = 4.1 Hz, C(4)), 136.6 (d, 3J(13C-19F) = 4.2 Hz, C(6)), 126.1 (s, C(1)), 125.2 (d, 2J(13C-19F) 
= 14.1 Hz, C(5)), 110.8 (s, C(3)), 55.9 (s, OCH3), 29.5 (s, CH2), 27.8 (s, CCH3), 20.7 (d,  
2J(13C-19F) = 12.4 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3): δ (ppm) = −189.0 (s,  
1J(19F-29Si) = 297 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.4 (d, 1J(29Si-19F) = 297 Hz). 
Elemental analysis calculated (%) for C16H26BrFOSi (360.09 g/mol): C 53.2, H 7.3; found (%): C 53.3, 
H 6.9. HR-MS (LC-ESI): calculated for C16H26O79BrF28Si [M]+ (m/z) 360.0915, found 360.0922; for 
C16H26O81BrF28Si [M]+ (m/z) 362.0894, found 362.0907. 
3-(Chloromethyl)-4-methoxyphenyl)-di-tert-butylfluorosilane (10d). The procedure was analogous to 
the synthesis of 10a starting from 9a (1.99 g, 4.82 mmol, 1.0 equiv.) and concentrated HCl (50 mL). 
Crystallisation from diethylether/hexane gave the product 10d (1.16 g, 3.66 mmol, 76%) as white 
crystalline solid of m.p. 64 °C. 1H-NMR (300.13 MHz, CDCl3): δ (ppm) = 7.54–7.49 (m, 2H, C(4)H 
und C(6)H), 6.89 (d, 3J(1H-1H) = 7.9 Hz, 1H, C(3)H), 4.64 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 1.03 (s, 
18H, CCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 158.5 (s, C(2)), 136.2 (d,  
3J(13C-19F) = 4.1 Hz, C(4)), 136.1 (d, 3J(13C-19F) = 4.2 Hz, C(6)), 125.2 (s, C(1)), 124.6 (d,  
2J(13C-19F) = 14.1 Hz, C(5)), 110.1 (s, C(3)), 55.3 (s, OCH3), 41.6 (s, CH2), 27.3 (s, CCH3), 20.2 (d, 
2J(13C-19F) = 12.5 Hz, C(CH3)3). Elemental analysis calculated (%) for C16H26ClFOSi (316.91 g/mol): 
C 60.6, H 8.3; found (%): C 60.8. HR-MS (LC-ESI): calculated for calculated for C16H26OF28Si 
[M−Cl−]+ (m/z) 281.1732, found 281.1733. 
5-(di-tert-Butylfluorosilyl)-2-methoxybenzaldehye (11a). To an ice-cooled and stirred suspension of 
pyridinium chlorochromate (2.86 g, 13.27 mmol, 3.0 equiv.) in dry CH2Cl2 (150 mL) was added  
drop-wise within 10 min a solution of 10a (1.32 g, 4.42 mmol) in dry CH2Cl2 (30 mL). The reaction 
mixture was stirred at room temperature for 2 h. After the reaction mixture had been diluted with 
diethyl ether (300 mL), the supernatant solution was decanted and the residue was washed with diethyl 
ether (2 × 100 mL). Filtration of the combined organic layers over a pad of silica and evaporation of 
the solvent afforded 11a (1.31 g, 4.42 mmol, quantitative) as a slightly yellowish amorphous solid, m.p.  
38 °C. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 10.43 (s, 1H, CHO), 8.00 (s, 1H, C(6)H), 7.73 (d,  
3J(1H-1H) = 8.3 Hz, 1H, C(4)H), 6.98 (d, 3J(1H-1H) = 8.3 Hz, 1H, C(3)H), 3.88 (s, 3H, OCH3), 0.98 (s, 
18H, CCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 189.6 (s, CHO), 162.7 (s, C(2)), 141.6 
(d, 3J(13C-19F) = 4.1 Hz, C(4)), 134.1 (d, 3J(13C-19F) = 4.3 Hz, C(6)), 129.9 (s, C(1)), 124.8 (d,  
2J(13C-19F) = 14.1 Hz, C(5)), 111.1 (s, C(3)), 55.4 (s, OCH3), 27.2 (s, CCH3), 20.1 (d, 2J(13C-19F) = 12.4 Hz, 
C(CH3)3). 19F-NMR (282.38 MHz, CDCl3): δ (ppm) = −188.6 (s, 1J(19F-29Si) = 298 Hz). 29Si-NMR 
(59.63 MHz, CDCl3): δ (ppm) = 14.3 (d, 1J(29Si-19F) = 298 Hz). Elemental analysis calculated (%) for 
C16H27FO2Si (296.45 g/mol): C 64.8, H 8.5; found (%): C 64.0, H 8.7. HR-MS (GC-EI): calculated for 
C16H25O2F28Si [M]+ (m/z): 296.1602; found 296.1601. 
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5-(di-tert-Butylfluorosilyl)-2,3-dimethoxybenzaldehyde (11b). The procedure was analogous to the 
synthesis of 11a. The alcohol 10b (3.04 g, 9.25 mmol) gave the aldehyde 11b (3.12 g, 9.25 mmol, 
quantitative) as a slightly yellowish amorphous solid of m.p. 73 °C. 1H-NMR (400.13 MHz, CDCl3):  
δ (ppm) = 10.36 (s, 1H, CHO), 7.55 (s, 1H, C(6)H), 7.28 (s, 1H, C(4)H), 3.93 (s, 3H, OCH3), 3.84 (s, 
3H, OCH3), 0.97 (s, 18H, CCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 189.9 (s, CHO), 
153.6.7 (s, C(2)), 152.3 (s, C(3)), 129.2 (d, 2J(13C-19F) = 14.2 Hz, C(5)), 128.9 (s, C(1)), 124.7 (d, 
3J(13C-19F) = 4.4 Hz, C(4)), 122.9 (d, 3J(13C-19F) = 4.2 Hz, C(6)), 62.0 (s, OCH3), 55.4 (s, OCH3), 27.1 
(s, CCH3), 20.1 (d, 2J(13C-19F) = 12.2 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3): δ (ppm) = −188.2 
(s, 1J(19F-29Si) = 298.9 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 13.9 (d, 1J(29Si-19F) = 299.0 Hz). 
Elemental analysis calculated (%) for C17H27FO3Si (326.48 g/mol): C 62.5, H 8.3; found (%): C 62.4, 
H 8.4. IR (KBr): ν (cm-1) = 1692 (ν (C=O)). HR-MS (GC-EI): calculated for C17H27O3FSi [M]+ (m/z): 
326.1708; found 326.1697. 
5-(di-tert-Butylfluorosilyl)-2-methoxybenzoic acid (12a). To a stirred solution of 11a (1.31 g, 4.42 mmol) 
in CH2Cl2 (5 mL) and t-BuOH (30 mL) one after another a buffered solution (30 mL, pH = 3) of 
NaH2PO4 (1.25 M), concentrated H3PO4 and an aqueous solution of KMnO4 (50 mL, 1 M) were added. 
Stirring was continued at room temperature for 3 h. The reaction mixture was quenched with saturated 
Na2SO3-solution (150 mL) and HCl (2 M). The latter reagents were added until the mixture turned 
colorless. After extraction with diethylether (3 × 200 mL) the combined organic layers were dried with 
MgSO4, filtered and the solvent was evaporated to afford 12a (1.01 g, 3.23 mmol, 73%) as a white 
amorphous solid that was re-crystallised from diethyl ether/hexane to give colorless crystals of m.p. 
123 °C. 1H-NMR (200 MHz, CDCl3): δ (ppm) = 8.40 (d, 4J(1H-1H) = 1.8 Hz, 1H, C(6)H), 7.81 (dd, 
3J(1H-1H) = 8.3 Hz, 4J(1H-1H) = 1.8 Hz, 1H, C(4)H), 7.09 (d, 3J(1H-1H) = 8.3 Hz, 1H, C(3)H), 4.09 (s, 
3H, OCH3), 1.04 (s, 18H, CCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 165.5 (s, COOH), 
159.8 (s, C(2)), 140.8 (d, 3J(13C-19F) = 4.0 Hz, C(4)), 139.2 (d, 3J(13C-19F) = 4.4 Hz, C(6)), 127.1  
(d, 2J(13C-19F) = 14.3 Hz, C(5)), 116.9 (s, C(1)), 111.1 (s, C(3)), 56.5 (s, OCH3), 27.2 (s, CCH3), 20.1 
(d, 2J(13C-19F) = 12.2 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3): δ (ppm) = −188.5 (s,  
1J(19F-29Si) = 298 Hz). Elemental analysis calculated (%) for C16H25FO3Si (312.45 g/mol): C 61.5, H 
8.1; found (%): C 61.1, H 7.9. HR-MS (GC-EI): calculated for C16H25O3FSi [M]+ (m/z): 312.1552; 
found 312.1563. IR (KBr): ν (cm−1) = 2989 (ν(OH)), 1701 (ν (C=O)). 
5-(di-tert-Butylfluorosilyl)-2,3-dimethoxybenzoic acid (12b). The procedure was analogous to the 
synthesis of 12a. The aldehyde 11b (2.00 g, 6.13 mmol) gave after re-crystallization from 
diethylether/hexane the carboxylic acid 12b (2.02 g, 5.90 mmol, 96%) as colorless crystals of m.p. 
118 °C. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 7.91 (s, 1H, C(6)H), 7.34 (s, 1H, C(4)H), 4.10  
(s, 3H, OCH3), 3.92 (s, 3H, OCH3), 1.04 (s, 18H, CCH3). 13C[1H]-NMR (100.63 MHz, C6D6):  
δ (ppm) = 166.8 (s, COOH), 152.4 (s, C(2)), 150.2 (s, C(3)), 130.1 (d, 2J(13C-19F) = 14.2 Hz, C(5)), 
129.3 (d, 3J(13C-19F) = 4.7 Hz, C(4)), 123.3 (s, C(1)), 122.0 (d, 3J(13C-19F) = 3.9 Hz, C(6)), 61.1 (s, 
OCH3), 55.2 (s, OCH3), 27.1 (s, CCH3), 20.1 (d, 2J(13C-19F) = 12.1 Hz, C(CH3)3). 19F-NMR (282.38 
MHz, CDCl3): δ (ppm) = −187.7 (s, 1J(19F-29Si) = 299 Hz). 29Si-NMR (59.63 MHz, CDCl3):  
δ (ppm) = 14.3 (d, 1J(29Si-19F) = 299 Hz). Elemental analysis calculated (%) for C17H27O4FSi (342.17 
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g/mol): C 59.6, H 8.0; found (%): C 59.4, H 7.6. HR-MS (GC-EI): calculated for C17H27O4FSi [M]+ 
(m/z): 342.1657; found 342.1641. IR (KBr): ν (cm−1) = 2974 (ν(OH)), 1685 (ν (C=O)). 
(S)-1-Allylpyrrolidine-2-carboxamide (14). The synthesis followed the same procedure as described in 
the literature [12]. The reaction of (S)-pyrrolinamide 13 (1.03 g, 9.02 mmol) with allyl iodide (0.83 mL, 
9.02 mmol, 1.0 equiv.) gave compound 14 (1.29 g, 8.37 mmol, 93%) as white amorphous solid.  
1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 7.19 (s, 1H, NH–H), 6.00 (s, 1H, NH–H), 5.87–5.76 (m, 
1H, CH=CH2), 5.20–5.04 (m, 2H, CH=CH2), 3.28 (dd, 3J1(1H-1H) = 13.6 Hz, 3J2(1H-1H) = 5.9 Hz, 1H, 
CH), 3.14–3.07 (m, 1H, CH–H), 3.06–2.99 (m, 2H, N–CH2–CH), 2.37–2.27 (m, 1H, CH–H), 2.21–2.09 
(m, 1H, CH–H), 1.91–1.81 (m, 1H, CH–H), 1.78–1.69 (m, 2H, CH2). 13C[1H]-NMR (100.63 MHz, 
CDCl3): δ (ppm) = 178.3 (s, CONH2), 135.1 (s, CH=CH2), 117.3 (s, CH=CH2), 66.7 (s, CH), 58.2 (s, 
CH2), 53.9 (s, CH2), 30.6 (s, CH2), 24.2 (s, CH2). HR-MS (LC-ESI): calculated for C8H15ON2 [M+H]+ 
(m/z): 155.1; found 155.2.  
(S)-(1-Allylpyrrolidine-2-yl)methanamine (15). The synthesis followed the same procedure as 
described in the literature [12]. The reaction of (S)-1-Allylpyrrolidine-2-carboxamide 14 (2.57 g,  
16.67 mmol) with DIBAL-solution (100 mL, 1 M in THF, 6.0 eq.) gave compound 15 (1.68 g, 11.98 
mmol, 72%) as slightly yellowish oil. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 5.71–5.57 (m, 1H, 
CH=CH2), 4.98–4.80 (m, 2H, CH=CH2), 3.16 (dd, 2J1(1H-1H) = 13.4 Hz, 3J(1H-1H) = 5.5 Hz, 1H, 
NH2CH–H), 2.86–2.79 (m, 1H, CH), 2.60 (dd, 2J(1H-1H) = 13.5 Hz, 3J(1H-1H) = 7.5 Hz, 1H,  
NH2CH–H), 2.48–2.42 (m, 2H, CH2), 2.22–1.92 (m, 2H, NH2), 1.69–1.41 (m, 6H, CH2CH2CH2). 
13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 136.1 (s, CH=CH2), 116.2 (s, CH=CH2), 65.1 (s, CH), 
57.5 (s, CH2), 54.1 (s, CH2), 44.2 (s, CH2NH2), 27.9 (s, CH2), 22.6 (s, CH2). 
(S)-N-((1-Allylpyrrolidine-2-yl)methyl)-5-(di-tert-butylfluorosilyl)-2-methoxybenzamide (SiFA-DMFP 
4a). To an ice-cooled solution in dry CHCl3 containing the substituted benzoic acid 12a (0.97 g,  
3.10 mmol), (S)-(1-Allylpyrrolidine-2-yl)methanamine 15 (0.43 g, 3.10 mmol, 1.0 equiv.) and pyridine 
(0.25 mL, 3.10 mmol, 1.0 equiv.) dicyclohexylcarbodiimide (0.64 g, 3.10 mmol, 1.0 equiv.) and  
N-hydroxysuccinimide (0.36 g, 3.10 mmol, 1.0 equiv.) were added under stirring. The mixture was 
stirred at 0 °C for 5 h and 17 h at ambient temperature. After the white precipitate had been filtered, 
the filtrate was washed with saturated NaHCO3-solution (20 mL) and subsequently with H2O (20 mL). 
After extracting the aqueous phase with diethyl ether (20 mL) the combined organic layers were dried 
with MgSO4, filtered and the solvent was evaporated to give an oily residue. The latter was purified by 
column chromatography (CHCl3/Ethanol = 20/1 → CHCl3/Ethanol = 10/1) to afford benzamide 4a 
(0.55 g, 1.27 mmol, 41%) as a yellowish oil. 1H-NMR (400.13 MHz, CDCl3): δ (ppm) = 8.44 (d, 
4J(1H-1H) = 1.4 Hz, 1H, C(6)H), 8.37 (d, 3J(1H-1H) = 3.8 Hz, 1H, NH), 7.68 (dd, 3J(1H-1H) = 8.2 Hz, 
4J(1H-1H) = 1.3 Hz, 1H, C(4)H), 7.00 (d, 3J(1H-1H) = 8.2 Hz, 1H, C(3)H), 5.96–5.84 (m, 1H, CH=CH2), 
5.24-5.06 (m, 2H, CH=CH2), 3.95 (s, 3H, OCH3), 3.75 (ddd, 2J(1H-1H) = 13.8 Hz, 3J(1H-1H) = 7.1 Hz, 
3J(1H-1H) = 3.1 Hz, 1H, NHCH–H), 3.48 (dd, 2J(1H-1H) = 13.5 Hz, 3J(1H-1H) = 5.3 Hz, 1H, 
CH2=CHCH-H), 3.35 (ddd, 2J(1H-1H) = 13.9 Hz, 3J(1H-1H) = 3.7 Hz, 3J(1H-1H) = 3.7 Hz, 1H, NHCH–H), 
3.19–3.13 (m, 1H, NCH–H), 2.91 (dd, 2J(1H-1H) = 13.5 Hz, 3J(1H-1H) = 7.5 Hz, 1H, CH2=CHCH–H), 
2.75 (s, 1H, CH), 2.33–2.22 (m, 1H, NCH–H), 1.99–1.85 (m, 1H, CH2CH2CH2), 1.79–1.61 (m, 3H, 
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CHCH2CH–H), 1.02 (s, 18H, CCH3). 13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 165.5 (s, 
CONH), 158.7 (s, C(2)), 138.6 (d, 3J(13C-19F) = 3.8 Hz, C(4)), 137.7 (d, 3J(13C-19F) = 4.7 Hz, C(6)), 
135.8 (s, CH=CH2), 125.3 (d, 2J(13C-19F) = 14.5 Hz, C(5)), 120.9 (s, C(1)), 116.2 (s, CH=CH2), 110.7 
(s, C(3)), 61.9 (s, CH), 57.0 (s, CH2CH=CH2), 55.5 (s, OCH3), 54.2 (s, NCH2), 41.3 (s, CH2NH), 28.5 
(s, CH2), 27.3 (s, CCH3), 22.9 (s, CH2), 20.2 (d, 2J(13C-19F) = 12.0 Hz, C(CH3)3). 19F-NMR (282.38 MHz, 
CDCl3): δ (ppm) = −188.8 (s, 1J(19F-29Si) = 298 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.4 
(d, 1J(29Si-19F) = 298 Hz). Elemental analysis calculated (%) for C24H39FN2O2Si·H2O (452.68 g/mol): 
C 63.7, H 9.1, N 6.2; found: C 64.1, H 9.1, N 6.3. HR-MS (LC-ESI): calculated for C24H40O2N2FSi 
[M+H]+ (m/z): 435.2838; found: 435.2832. 
(S)-N-((1-Allylpyrrolidine-2-yl)methyl)-5-(di-tert-butylfluorosilyl)-2,3-dimethoxybenzamide (SiFA-FP, 
4b). The procedure was analogous to the synthesis of 4a. The reaction of the benzoic acid derivative 
12b (1.47 g, 4.28 mmol) with (S)-(1-Allylpyrrolidine-2-yl)methanamine 15 (0.60 g, 3.10 mmol, 1.0 equiv.) 
gave SiFA-FP 4b (0.81 g, 1.74 mmol, 41%) as a yellowish oil. 1H-NMR (400.13 MHz, CDCl3):  
δ (ppm) = 8.51 (s, br, 1H, NH), 7.93 (s, 1H, C(4)H), 7.24 (s, 1H, C(6)H), 5.99–5.87 (m, 1H, CH=CH2), 
5.27-5.09 (m, 2H, CH=CH2), 3.93 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.80 (ddd, 2J(1H-1H) = 13.9 Hz, 
3J(1H-1H) = 6.9 Hz, 3J(1H-1H) = 3.6 Hz, 1H, NHCH–H), 3.54 (dd, 2J(1H-1H) = 13.5 Hz, 3J(1H-1H) = 5.3 Hz, 
1H, CH2=CHCH–H), 3.47–3.37 (m, 1H, NHCH–H), 3.19–3.13 (m, 1H, NCH–H), 2.98 (dd,  
2J(1H-1H) = 13.2 Hz, 3J(1H-1H) = 7.6 Hz, 1H, CH2=CHCH–H), 2.86 (s, 1H, CH), 2.39–2.29 (m, 1H, 
NCH–H), 2.03–1.91 (m, 1H, CH2CH2CH2), 1.87–1.67 (m, 3H, CHCH2CH–H), 1.05 (s, 18H, CCH3). 
13C[1H]-NMR (100.63 MHz, CDCl3): δ (ppm) = 165.5 (s, CONH), 151.9 (s, C(2)), 148.8 (s, C(3)), 
134.6 (s, CH=CH2), 129.4 (d, 2J(13C-19F) = 14.0 Hz, C(5)), 128.4 (d, 3J(13C-19F) = 4.7 Hz, C(4)), 125.8 
(s, C(1)), 120.3 (d, 3J(13C-19F) = 3.9 Hz, C(6)), 117.9 (s, CH=CH2), 62.2 (s, CH), 61.2 (s, OCH3), 57.0 
(s, CH2CH=CH2), 56.0 (s, OCH3), 53.9 (s, NCH2), 41.0 (s, CH2NH), 28.4 (s, CH2), 27.3 (s, CCH3), 
22.6 (s, CH2), 20.2 (d, 2J(13C-19F) = 12.2 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3):  
δ (ppm) = −188.5 (s, 1J(19F-29Si) = 298 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.2 (d, 
1J(29Si-19F) = 299 Hz). Elemental analysis calculated (%) for C25H41FN2O3Si·H2O (482.70 g/mol): C 
62.2, H 9.0, N 5.8; found (%): C 61.9, H 8.6, N 4.9. HR-MS (LC-ESI): calculated for C25H42O3N2FSi 
[M+H]+ (m/z): 465.2943; found: 465.2924. 
(S)-N-((1-Allylpyrrolidine-2-yl)methyl)-4-(di-tert-butylfluorosilyl) benzamide (SiFA-DDMFP, 4c). The 
procedure was analogous to the synthesis of 4a. The reaction of the benzoic acid derivative 12c [17] 
(0.50 g, 1.77 mmol) with (S)-(1-Allylpyrrolidine-2-yl)methanamine 15 (0.25 g, 1.77 mmol, 1.0 equiv.) 
gave SiFA-DDMFP 11c (0.08 g, 0.20 mmol, 11%) as a yellowish oil. 1H-NMR (400.13 MHz, CDCl3): 
δ (ppm) = 7.80 (d, 3J(1H-1H) = 7.7 Hz, 2H, Ho), 7.69 (d, 3J(1H-1H) = 8.0 Hz, 2H, Hm), 7.00 (s, 1H, 
NH) 5.99–5.86 (m, 1H, CH=CH2), 5.29–5.12 (m, 2H, CH=CH2), 3.73 (ddd, 2J(1H-1H) = 13.7 Hz,  
3J(1H-1H) = 7.4 Hz, 3J(1H-1H) = 3.2 Hz, 1H, NHCH–H), 3.50–3.43 (m, 2H), 3.2 (s, 1H), 3.04–2.76 (m, 
2H), 2.42–2.28 (m, 1H), 1.92–1.90 (m, 1H), 1.64–1.54 (m, 3H), 1.06 (s, 18H, CCH3). 13C[1H]-NMR 
(100.63 MHz, CDCl3): δ (ppm) = 167.8 (s, CONH), 137.9 (d, 2J(13C-19F) = 13.7 Hz, Cp), 135.2 (s, Ci), 
134.1 (d, 3J(13C-19F) = 4.7 Hz, Cm), 134.1 (s, CH=CH2), 126.0 (s, Co), 117.4 (s, CH=CH2), 62.8 (s, 
CH), 57.4 (s, CH2CH=CH2), 54.1 (s, NCH2), 40.7 (s, CH2NH), 28.2 (s, CH2), 27.2 (s, CCH3), 23.1 (s, 
CH2), 20.2 (d, 2J(13C-19F) = 12.3 Hz, C(CH3)3). 19F-NMR (282.38 MHz, CDCl3): δ (ppm) = −189.2  
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(s, 1J(19F-29Si) = 299 Hz). 29Si-NMR (59.63 MHz, CDCl3): δ (ppm) = 14.0 (d, 1J(29Si-19F) = 299 Hz). 
Elemental analysis calculated (%) for C23H37FN2OSi·H2O + C8H16N2 (562.88 g/mol): C 66.2, H 9.5, N 
8.4; found (%): C 66.0, H 9.2, N 8.2. HR-MS (LC-ESI): calculated for C23H37ON2FSi [M+H]+ (m/z): 
405.2732; found: 405.2726. 
(S)-N-((1-Allylpyrrolidin-2-yl)methyl)-5-(3-(1-(4-(di-tert-butylfluorosilyl)phenyl)-2,5-dioxopyrrolidin-
3-ylthio)propyl)-2,3-dimethoxybenzamide (SiFA-M-FP, 5). To a freshly prepared solution of 1-(4-(di-
tert-butylfluorosilyl)phenyl)-1H-pyrrole-2,5-dione (SiFA-maleimide, [17]) (3 mg, 9 µmol) in phosphate 
buffer (PB, 0.1 M, pH 6.0) and acetonitrile (1:1) was added a solution of (S)-N-((1-allylpyrrolidin-2-
yl)methyl)-5-(3-mercaptopropyl)-2,3-dimethoxybenzamide (FP-thiol) (3.4 mg, 9 µmol) in acetonitrile 
(100 µL) and the pH of the solution was adjusted to 7.2 using PB (0.1M, pH = 7.2, 200 µL). After  
10 min, the product was isolated by semi-preparative HPLC applying a gradient of 40%–80% 
acetonitrile in 10 minutes. The product was obtained as white powder after lyophilization (3.1 mg,  
4.4 µmol, 49% yield). ESI-MS calculated for [M+H]+ (m/z): 712.35, found: 712.36. 
3.4. In Vitro Binding Assay 
Evaluation of the dopamine D2-receptor binding affinity: The substances were dissolved in water or 
DMSO-water mixtures, respectively, and evaluated according to the [3H]spiperone binding protocol 
published by Malmberg and coworkers [21]. Source of the dopamine-D2-receptors was cell line 
HEK293 which expresses the D2 receptors stably. The Kd-value of [3H]spiperone was determined in 
three saturation experiments (41.0 ± 6.0 pM (± SEM), pKd: 9.398 ± 0.067). All substances were evaluated 
in 3 independent competition experiments in six concentrations (each in triplicate). The Ki-values were 
calculated from the IC50-values according to Cheng-Prusoff [22] as described in detail in [23]. 
3.5. Radiolabeling 
General procedure for the labeling of SiFA-compounds. Aqueous [18F]fluoride (4000–7500 MBq) 
produced by the 18O(p,n)18F nuclear reaction on an enriched [18O]water (95%) target was loaded onto a 
Chromafix PS-HCO3 cartridge and eluted with a mixture of acetonitrile (800 µL), water (200 µL), 
potassium oxalate solution (1 M, 10 µL), and Kryptofix 2.2.2 (12.5 mg) (procedure a) or eluted with a 
mixture of 800 μL acetonitrile and 300 μL aqueous tetrabutylammonium hydrogen carbonate solution 
(0.075 mol/L, ABX, Radeberg, Germany) (procedure b). The solvents were removed by coevaporation 
to dryness under reduced pressure (650 mbar) using a stream of helium at 90 °C for 4 min. The drying 
step was repeated twice with acetonitrile (0.8 mL) (3 min) and full vacuum (~10 mbar) was applied in 
the final drying step (4 min). The dried [18F]F-complex was dissolved in dry acetonitrile, DMF or 
DMSO, respectively, (500–1000 µL) and used as stock solution for labeling. The labeling precursors 
(1–2 mg) were dissolved in dry acetonitrile, DMF or DMSO, respectively (1 µmol/mL) and aliquots 
containing 5–10 nmol of these stock solutions (5–10 µL) were used for labeling and incubated with 
250 µL of the 18F stock solutions. After 5 min reaction time at ambient temperature (without stirring), 
samples were withdrawn from the reaction mixture and analyzed by analytical HPLC. For purification, 
the reaction mixture was diluted with 10 mL HEPES-buffer (1 M, pH = 4.0) and loaded on a SepPak  
C-18 light cartridge (Waters, Germany), preconditioned with 5mL ethanol and 5mL isotonic saline. 
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The cartridge was washed with 10 mL isotonic saline and subsequently eluted with 1 mL ethanol. 
After dilution with 9 mL isotonic saline the radiotracers were measured, analyzed by radio-HPLC and 
used for plasma stability experiments. 
In vitro stability in human plasma. To human plasma (500 µL) at 37 °C were added 10–100 MBq of 
the injectable solutions. The mixture was incubated at 37 °C. After 90 min, aliquots (75 µL, in 
triplicate) were removed and treated with acetonitrile (75 µL). Samples were then stored on ice for  
5 min for complete precipitation of the plasma proteins. The precipitate was removed by centrifugation, 
and the supernatants were analyzed by radio-HPLC. Radioactivity in precipitate and supernatant  
was measured. 
4. Conclusions 
Motivated by our recent development of a kit-like radiolabeling strategy for the introduction of  
18F-fluoride into proteins and target-specific peptides using Silicon-Fluoride-Acceptors (SiFAs) and 
their application in preclinical studies, we synthesized a series of SiFA-containing fallypride/ 
desmethoxyfallypride derivatives (Figure 2). Compared to other medium-affinity D2-receptor ligands 
such as DMFP 2, the compounds showed a reduced affinity to the targeted receptor. However, the 
affinity is still in the nanomolar range and should therefore be high enough for an in vivo application. 
The radiochemical synthesis of the potential radiotracers, most notably the synthesis time of only  
10 min and the easy cartridge purification, could be a breakthrough in radiofluorinations of  
small-molecule radiotracers. However, the potential of these SiFA-radiotracers remains to be shown in 
ongoing in vitro studies regarding receptor subtype-selectivity as well as Pgp-activity and finally in 
preclinical in vivo studies. 
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